Annual CFF
-$34.97 M
-$6.13 M-21.24%
31 December 2023
Summary:
REGENXBIO annual cash flow from financing activities is currently -$34.97 million, with the most recent change of -$6.13 million (-21.24%) on 31 December 2023. During the last 3 years, it has fallen by -$235.18 million (-117.46%). RGNX annual CFF is now -114.61% below its all-time high of $239.31 million, reached on 31 December 2015.RGNX Cash From Financing Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Quarterly CFF
-$10.86 M
-$1.41 M-14.95%
30 September 2024
Summary:
REGENXBIO quarterly cash flow from financing activities is currently -$10.86 million, with the most recent change of -$1.41 million (-14.95%) on 30 September 2024. Over the past year, it has dropped by -$6.05 million (-125.95%). RGNX quarterly CFF is now -105.14% below its all-time high of $211.29 million, reached on 31 March 2021.RGNX Quarterly CFF Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
TTM CFF
$88.46 M
-$6.05 M-6.40%
30 September 2024
Summary:
REGENXBIO TTM cash flow from financing activities is currently $88.46 million, with the most recent change of -$6.05 million (-6.40%) on 30 September 2024. Over the past year, it has increased by +$120.39 million (+377.10%). RGNX TTM CFF is now -78.36% below its all-time high of $408.74 million, reached on 31 March 2021.RGNX TTM CFF Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
RGNX Cash From Financing Performance
| PeriodPeriod | AnnualAnnual | QuarterlyQuarterly | TTMTTM |
|---|---|---|---|
| 1 y1 year | -21.2% | -126.0% | +377.1% |
| 3 y3 years | -117.5% | -375.6% | -77.7% |
| 5 y5 years | -117.1% | -914.5% | +630.2% |
RGNX Cash From Financing High & Low
| PeriodPeriod | Annual vs highAnnual vs high | Annual vs lowAnnual vs low | Quarter. vs highQuarter. vs high | Quarter. vs lowQuarter. vs low | TTM vs highTTM vs high | TTM vs lowTTM vs low | |
|---|---|---|---|---|---|---|---|
| 3 y | 3 years | -117.5% | at low | -109.0% | +9.2% | -77.7% | +353.0% |
| 5 y | 5 years | -117.1% | at low | -105.1% | +9.2% | -78.4% | +353.0% |
| alltime | all time | -114.6% | at low | -105.1% | +9.2% | -78.4% | +353.0% |
REGENXBIO Cash From Financing History
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| Sept 2024 | - | -$10.86 M(+14.9%) | $88.46 M(-6.4%) |
| June 2024 | - | -$9.45 M(-107.8%) | $94.51 M(-0.3%) |
| Mar 2024 | - | $120.72 M(-1109.2%) | $94.80 M(-371.1%) |
| Dec 2023 | -$34.97 M(+21.2%) | -$11.96 M(+148.9%) | -$34.97 M(+9.5%) |
| Sept 2023 | - | -$4.80 M(-47.6%) | -$31.92 M(-1.9%) |
| June 2023 | - | -$9.16 M(+1.4%) | -$32.54 M(+4.8%) |
| Mar 2023 | - | -$9.04 M(+1.3%) | -$31.04 M(+7.6%) |
| Dec 2022 | -$28.84 M(-114.8%) | -$8.92 M(+64.7%) | -$28.84 M(+4.7%) |
| Sept 2022 | - | -$5.42 M(-29.4%) | -$27.54 M(+12.8%) |
| June 2022 | - | -$7.67 M(+12.2%) | -$24.40 M(+6.7%) |
| Mar 2022 | - | -$6.83 M(-10.3%) | -$22.87 M(-111.7%) |
| Dec 2021 | $195.25 M(-2.5%) | -$7.62 M(+233.6%) | $195.25 M(-50.8%) |
| Sept 2021 | - | -$2.28 M(-62.8%) | $397.03 M(-0.9%) |
| June 2021 | - | -$6.14 M(-102.9%) | $400.78 M(-1.9%) |
| Mar 2021 | - | $211.29 M(+8.8%) | $408.74 M(+104.2%) |
| Dec 2020 | $200.21 M(+2290.3%) | $194.17 M(>+9900.0%) | $200.21 M(+2536.1%) |
| Sept 2020 | - | $1.46 M(-20.0%) | $7.59 M(+1.7%) |
| June 2020 | - | $1.82 M(-33.9%) | $7.47 M(+6.5%) |
| Mar 2020 | - | $2.76 M(+78.2%) | $7.01 M(-16.3%) |
| Dec 2019 | $8.38 M | $1.55 M(+16.2%) | $8.38 M(-30.9%) |
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| Sept 2019 | - | $1.33 M(-2.5%) | $12.12 M(-94.0%) |
| June 2019 | - | $1.37 M(-66.9%) | $202.60 M(-0.9%) |
| Mar 2019 | - | $4.13 M(-22.0%) | $204.40 M(-0.0%) |
| Dec 2018 | $204.44 M(+141.7%) | $5.29 M(-97.2%) | $204.44 M(+1.8%) |
| Sept 2018 | - | $191.81 M(+5941.4%) | $200.90 M(+1973.7%) |
| June 2018 | - | $3.17 M(-23.8%) | $9.69 M(-43.8%) |
| Mar 2018 | - | $4.17 M(+139.3%) | $17.24 M(-79.6%) |
| Dec 2017 | $84.60 M(>+9900.0%) | $1.74 M(+187.3%) | $84.60 M(+2.2%) |
| Sept 2017 | - | $606.00 K(-94.4%) | $82.80 M(+0.7%) |
| June 2017 | - | $10.73 M(-85.0%) | $82.24 M(+14.8%) |
| Mar 2017 | - | $71.52 M(<-9900.0%) | $71.62 M(>+9900.0%) |
| Dec 2016 | $119.00 K(-100.0%) | -$55.00 K(-225.0%) | $119.00 K(-105.3%) |
| Sept 2016 | - | $44.00 K(-59.6%) | -$2.25 M(-101.5%) |
| June 2016 | - | $109.00 K(+419.0%) | $145.35 M(-31.9%) |
| Mar 2016 | - | $21.00 K(-100.9%) | $213.30 M(-10.9%) |
| Dec 2015 | $239.31 M(+9867.1%) | -$2.42 M(-101.6%) | $239.31 M(-1.0%) |
| Sept 2015 | - | $147.65 M(+116.9%) | $241.73 M(+156.9%) |
| June 2015 | - | $68.06 M(+161.5%) | $94.09 M(+261.5%) |
| Mar 2015 | - | $26.03 M | $26.03 M |
| Dec 2014 | $2.40 M(+22.2%) | - | - |
| Dec 2013 | $1.97 M | - | - |
FAQ
- What is REGENXBIO annual cash flow from financing activities?
- What is the all time high annual CFF for REGENXBIO?
- What is REGENXBIO annual CFF year-on-year change?
- What is REGENXBIO quarterly cash flow from financing activities?
- What is the all time high quarterly CFF for REGENXBIO?
- What is REGENXBIO quarterly CFF year-on-year change?
- What is REGENXBIO TTM cash flow from financing activities?
- What is the all time high TTM CFF for REGENXBIO?
- What is REGENXBIO TTM CFF year-on-year change?
What is REGENXBIO annual cash flow from financing activities?
The current annual CFF of RGNX is -$34.97 M
What is the all time high annual CFF for REGENXBIO?
REGENXBIO all-time high annual cash flow from financing activities is $239.31 M
What is REGENXBIO annual CFF year-on-year change?
Over the past year, RGNX annual cash flow from financing activities has changed by -$6.13 M (-21.24%)
What is REGENXBIO quarterly cash flow from financing activities?
The current quarterly CFF of RGNX is -$10.86 M
What is the all time high quarterly CFF for REGENXBIO?
REGENXBIO all-time high quarterly cash flow from financing activities is $211.29 M
What is REGENXBIO quarterly CFF year-on-year change?
Over the past year, RGNX quarterly cash flow from financing activities has changed by -$6.05 M (-125.95%)
What is REGENXBIO TTM cash flow from financing activities?
The current TTM CFF of RGNX is $88.46 M
What is the all time high TTM CFF for REGENXBIO?
REGENXBIO all-time high TTM cash flow from financing activities is $408.74 M
What is REGENXBIO TTM CFF year-on-year change?
Over the past year, RGNX TTM cash flow from financing activities has changed by +$120.39 M (+377.10%)